CATABASIS PHARMACEUTICALS INC

FREE EMAIL WATCHDOG

Get free email notifications about news in CATABASIS PHARMACEUTICALS INC.

The service is free and you can unsubscribe at any time.

General | People (42) | Filings (138) | Investment rounds (8) | Annual reports (2) | Stock | News

Industry: PHARMACEUTICAL PREPARATIONS [2834]

CIK Number: 0001454789

CATABASIS PHARMACEUTICALS INC is a publicly traded company

Trading symbol: CATB

CATABASIS PHARMACEUTICALS INC is on the market more than 5 years.

News

2017-10-18

Let's Get Complex With Catabasis Pharmaceuticals, Inc. (CATB) And Marathon Oil ...
Post Analyst
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) traded at an unexpectedly low level on 10/17/2017 when the stock experienced a -2.97% loss to a closing price of $2.29.

2017-10-18

FY2019 EPS Estimates for Catabasis Pharmaceuticals, Inc. (CATB) Cut by Analyst
The Ledger Gazette
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) - Investment analysts at Wedbush reduced their FY2019 earnings estimates for Catabasis Pharmaceuticals in a research report issued to clients and investors on Wednesday.

2017-10-18

Catabasis Pharmaceuticals' (CATB) Market Perform Rating Reaffirmed at Cowen ...
TrueBlueTribune
Catabasis Pharmaceuticals logo Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)'s stock had its “market perform” rating reissued by equities researchers at Cowen and Company in a research note issued on Friday, October 6th.
Zacks Investment Research Downgrades Catabasis Pharmaceuticals, Inc. (CATB) to ... - Dispatch Tribunal
Catabasis Pharmaceuticals, Inc. (CATB) Given Average Recommendation of “Buy ... - Week Herald

2017-10-17

Making News: An Update on Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)
Nelson Research
The micro cap world has been buzzing about shares of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) as its stock price changed -3.81%, hitting $2.27 after the completion of a recent trading session.

2017-10-17

Catabasis Pharmaceuticals' (CATB) “Outperform” Rating Reaffirmed at CIBC
StockNewsTimes
Catabasis Pharmaceuticals logo Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB)'s stock had its “outperform” rating reiterated by analysts at CIBC in a note issued to investors on Thursday, October 5th.
Catabasis Pharmaceuticals, Inc. (CATB) Downgraded to “Hold” at Zacks ... - TrueBlueTribune
Catabasis Pharmaceuticals (CATB) Earning Somewhat Positive Press Coverage ... - The Ledger Gazette

2017-10-16

Catabasis Pharmaceuticals, Inc. (CATB) Downgraded by Zacks Investment Research ...
The Ledger Gazette
Catabasis Pharmaceuticals logo Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Monday.
Analysts See $-0.34 EPS for Catabasis Pharmaceuticals Inc (CATB) - BZ Weekly
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) Among Today's Most Volatile ... - HugoPress

2017-10-14

Price Alert: Catabasis Pharmaceuticals Inc (NASDAQ:CATB) Stock Nears ...
CML News
Price Alert: Catabasis Pharmaceuticals Inc (NASDAQ:CATB) has now crossed into technical strength -- watch the technical oscillators for momentum gaps.

CATABASIS PHARMACEUTICALS INC address

ONE KENDALL SQUARE
BLDG. 1400E, SUITE B14202
CAMBRIDGE
02139

Company jurisdiction

DELAWARE

Entity type

Corporation

Earliest known filing

January 2009

Latest known filing

October 2017

Company filings

SEC filings are a great source of information for companies including investments, company events, and all sorts of other information.

CATABASIS PHARMACEUTICALS INC has 138 filings. View CATABASIS PHARMACEUTICALS INC filings.

Annual Reports

Quarterly Reports

Latest company events

Investment Rounds

CATABASIS PHARMACEUTICALS INC recieved 8 investments.

People

We have found 42 people related to CATABASIS PHARMACEUTICALS INC.